Orchestra BioMed Appoints Chief Medical Officer

Dr. Donohoe brings nearly 30 years of clinical and regulatory experience

Orchestra BioMed, Inc. has appointed Dennis Donohoe, M.D., as chief medical officer. Dr. Donohoe is a leading clinical development expert with an outstanding track record of success in steering high-impact therapeutic devices through clinical trials and regulatory approvals, including the CYPHER® sirolimus-eluting stent, the first FDA approved drug-eluting stent, for which he oversaw global registrational clinical development during his tenure as worldwide vice president of clinical, regulatory ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters